Sort
25,944 grants matching “neurodegeneration”
Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial
$733,468Kent E Hutchison · University Of Colorado Denver · R01 · FY2023 · AG
Clarifying the overlapping pathology of delirium and dementia
$733,240Robert A Pearce · University Of Wisconsin-Madison · R01 · FY2020 · AG
Variant to gene mapping for Alzheimer's Disease
$733,237Struan F A Grant · Children'S Hosp Of Philadelphia · R01 · FY2019 · AG
Brain Temperature, Reward, And Drugs Of Abuse
$733,042Eugene A Kiyatkin · National Institute On Drug Abuse · Z01 · FY2007 · DA
National Cohort Studies of Alzheimer's Disease, Related Dementias and Air Pollution
$732,992Antonella Zanobetti · Harvard School Of Public Health · R01 · FY2021 · AG
National Cohort Studies of Alzheimer's Disease, Related Dementias and Air Pollution
$732,992Antonella Zanobetti · Harvard School Of Public Health · R01 · FY2023 · AG
Neurodegeneration and Brain Function in Aging with HIV and Parkinson's Disease
$732,881Tilman Schulte · Sri International · R01 · FY2015 · AA
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers
$732,693Clifford Jack · Mayo Clinic Rochester · R37 · FY2022 · AG
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers
$732,693Clifford Jack · Mayo Clinic Rochester · R37 · FY2021 · AG
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers
$732,693Clifford Jack · Mayo Clinic Rochester · R37 · FY2019 · AG
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers
$732,693Clifford Jack · Mayo Clinic Rochester · R37 · FY2018 · AG
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers
$732,693Clifford Jack · Mayo Clinic Rochester · R37 · FY2020 · AG
Clinical Core
$732,587Lon S Schneider · University Of Southern California · P50 · FY2019 · AG
Reversal of HIV latency by METH and Inflammation
$732,546Jonathan Karn · Case Western Reserve University · R01 · FY2017 · DA
Structural and functional insights into large-pore channels
$732,475Hiroyasu Furukawa · Cold Spring Harbor Laboratory · R01 · FY2025 · NS
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system
$732,392Clifford Jack · Mayo Clinic Rochester · R01 · FY2021 · AG
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system
$732,392Clifford Jack · Mayo Clinic Rochester · R01 · FY2020 · AG
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system
$732,392Clifford Jack · Mayo Clinic Rochester · R01 · FY2017 · AG
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system
$732,392Clifford Jack · Mayo Clinic Rochester · R01 · FY2018 · AG
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system
$732,392Clifford Jack · Mayo Clinic Rochester · R01 · FY2019 · AG
High throughput tau oligomer assay for drug screening for Alzheimer's disease
$732,203James G. Moe · Oligomerix, Inc · R44 · FY2011 · AG
Polyalanine Tails: A Novel Type of Protein Modification Implicated in Neurodegeneration
$732,174Robert W Burgess · Jackson Laboratory · R01 · FY2023 · NS
Using connectomics to characterize risk for Alzheimer's Disease
$732,130Jane E Joseph · Medical University Of South Carolina · R01 · FY2021 · AG
Antisense Oligonucleotides targeting APP to prevent neurodegeneration in models of Down Syndrome and Alzheimer's disease
$732,109William C Mobley · University Of California, San Diego · R01 · FY2021 · AG
Reversal of HIV latency by METH and Inflammation
$731,921Jonathan Karn · Case Western Reserve University · R01 · FY2019 · DA